)
Visual
test
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum (SOBI) investor relations material
Swedish Orphan Biovitrum Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Feb, 2026
Executive summary
Achieved 16% Q4 revenue growth at constant currency, with 37% growth in the strategic portfolio and strong performance across all regions, driven by innovative medicines and new product launches.
Full-year 2025 revenue grew 15% at constant currency, with all regions contributing and a 40% adjusted EBITDA/EBITA margin, reflecting operational excellence and cost alignment.
Strategic acquisitions, notably Arthrosi Therapeutics, and product launches such as Aspaveli and Olezarsen, have strengthened the pipeline and positioned the business for future leadership in key therapeutic areas.
Six high-value medicines are expected to launch by 2028, radically transforming the company’s trajectory.
Significant pipeline progress with pivotal Tryngolza data, Gamifant proof-of-concept, and regulatory submissions for Aspaveli and NASP.
Financial highlights
Q4 revenues reached SEK 7,821M, up 16% at constant currencies; full-year revenue was SEK 28,238M, up 15% at CER.
Adjusted gross margin improved to 81% in Q4 (from 78% prior year); full-year adjusted gross margin was 79%.
Q4 adjusted EBITDA/EBITA margin was 41%, up from 34% last year; full-year margin reached 40% (up 4 points year-over-year).
Q4 profit for the period was SEK 1,862M, up 34% year-over-year; adjusted EPS before dilution was SEK 5.70, up 42%.
Operating cash flow for Q4 was SEK 2,981M, up 66% year-over-year; net debt at year-end was SEK 10,081M.
Outlook and guidance
2026 revenue expected to grow at a low double-digit percentage at CER, with adjusted EBITDA/EBITA margin anticipated in the mid-30s percentage of revenue.
Significant investments planned in 2026 for launches and development, including Aspaveli, Olezarsen, Arthrosi, and Gamifant, which will moderate EBITDA/EBITA margin.
No dividend proposed for 2025.
Key drivers include continued Altuvoct launch, investments in Aspaveli and NASP, Tryngolza filing, and incorporation of Arthrosi.
Vonjo's path to growth post-impairment
Explain 2026 adjusted EBITA margin decline
Pipeline/acquisitions' role in long-term growth
Gamifant sepsis: next trial path and timeline?
Quantify Arthrosi's 2026 margin impact
Beyfortus: factors influencing 2026 outlook?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Swedish Orphan Biovitrum earnings date
CMD 202618 Feb, 2026
Swedish Orphan Biovitrum
Next Swedish Orphan Biovitrum earnings date
CMD 202618 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage